

MODERN VACCINES ADJUVANTS FORMULATION

2-4 May 2018, LUMC – Leiden University Medical Center, Leiden, The Netherlands

FINAL ORAL & POSTER PROGRAMME MVAF 2018

SCIENTIFIC ADVISORY PANEL

Conference Chairman: Dennis Christensen (*SSI, Copenhagen, Denmark*)

Jean Haensler (*Sanofi Pasteur, Lyon, France*)

Manmohan Singh (*Takeda Vaccines Inc., Cambridge, Massachusetts, USA*)

Heather Davis (*Pfizer Vaccines Research, Ottawa, Canada*)

Chris Fox (*IDRI, Seattle, Washington, USA*)

Nicolas Collin (*University of Lausanne, Lausanne, Switzerland*)

Maria Lazaro (*SEPPIC, Paris, France*)

Ken Ishii (*University of Osaka, Osaka, Japan*)

Erik Lindblad (*Brenntag Biosector, Frederikssund, Denmark*)

Gideon Kersten (*Intravacc, Bilthoven, The Netherlands*)

Martin Bachmann (*University of Berne, Berne, Switzerland*)

Ferry A. Ossendorp (*Leiden University Medical Center, Leiden, The Netherlands*)

Kees Melief (*ISA-Pharmaceuticals BV, Leiden, The Netherlands*)

Ed Remarque (*BPRC, Rijswijk, The Netherlands*)

Geert Vanden Bossche (*COIMEVA LLC, Huldenberg, Belgium*)

Raja Rajaram (*Seqiris, Maidenhead, Berkshire, UK*)

Bror Morein (*Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden*)

Charles Lutsch (*Sanofi Pasteur, Marcy l'Etoile, France*)

BRENNTAG

SEPPIC

inovio
PHARMACEUTICALS



NatureGeneTherapy.com
Gene-based vaccines & therapy research

aldevron

DNAvaccine.com

CUREVAC
the RNA people®

BIOASTER
MICROBIOLOGY TECHNOLOGY INSTITUTE

IDRIX

intravacc
innovating vaccines

hVIVO
better treatments, faster

SANOFI PASTEUR

VAXART

08.30 Onwards

Registration

SESSION 1: PLENARY SESSION I

Moderator: Tom H.M. Ottenhoff

(Leiden University Medical Center, Leiden, The Netherlands)

09.30-10.00

'Defined adjuvants for cancer vaccines'

Ferry A. Ossendorp

(Leiden University Medical Center, Leiden, The Netherlands)

10.00-10.30

'Translational Vaccinology: A myth?'

Geert Vanden Bossche

(COIMEVA LLC, Huldenberg, Belgium)

10.30-11.00

'Translating adjuvant science to the real world: Not a 100 metre dash'

Raja Rajaram

(Seqirus, Maidenhead, Berkshire, UK)

11.00-11.30

Coffee Break

SESSION 2: PLENARY SESSION II

Moderator: Geert Vanden Bossche

(COIMEVA LLC, Huldenberg, Belgium)

11.30-12.00

'Host directed therapy by immunostimulants and novel compounds'

Tom H.M. Ottenhoff

(Leiden University Medical Center, Leiden, The Netherlands)

12.00-12.30

'Distinct adjuvants requirement for induction of T versus B cell responses'

Martin Bachmann

(University of Berne, Berne, Switzerland / University of Oxford, Oxford, UK)

12.30-13.00

'Vaccine formulation a matter for accomplishment'

Dennis Christensen

(Statens Serum Institut, Copenhagen, Denmark)

13.00-14.00

Lunch Break

SESSION 3: PLENARY SESSION III

Moderator: Dennis Christensen

(Statens Serum Institut, Copenhagen, Denmark)

14.00-14.30

'Anti-tumour vaccines: An update'

Kees Melief

(ISA-Pharmaceuticals BV, Leiden, The Netherlands)

14.30-15.00

'Immune-engineering antigens for better vaccine design'

Lenny Moise

(EpiVax Inc., Providence, Rhode Island, USA)

15.00-15.30

'Opportunities and challenges in characterizing the safety of new adjuvants'

Thomas Verstraeten, Marc Baay and Kaatje Bollaerts

(P95 Epidemiology and Pharmacovigilance Services, Leuven, Belgium)

15.30-16.00

Tea Break

SESSION 4: VIRUS TOPICS

Moderator: Martin Bachmann

(University of Berne, Berne, Switzerland / University of Oxford, Oxford, UK)

16.00-16.30

'A virosomal RSV vaccine containing the 3D-PHAD® adjuvant based on thermostable virus'

Toon Stegmann

(Mymetics BV, Leiden, The Netherlands)

16.30-17.00

'Mucosal immunity may be the missing link to improve the poor and variable efficacy of flu vaccines: Protection by intranasal vaccination with Nanostat®-Pandemic flu (rH5) in ferrets'

Ali Fattom, Doug Smith and Vira Bitko

(NanoBio Corp., Ann Arbor, Michigan, USA)

17.00-17.30

'VLPs for veterinary medicine: Transforming the success of human monoclonal antibodies into effective and affordable medicines for companion animals'

Martin Bachmann

(Inselspital, Bern, Switzerland / University of Oxford, Oxford, UK)

SESSION 5: PLENARY SESSION IV

Moderator: Ken Ishii

(University of Osaka, Osaka, Japan)

09.00-09.30

'TB Vaccines overview'

Tom H.M. Ottenhoff

(Leiden University Medical Center, Leiden, The Netherlands)

09.30-10.00

'Chitosan-based adjuvants: Biopolymer characteristics determine immunogenicity for inactivated influenza vaccines'

Yuri Vasiliev

(State Research Institute of Ultrapure Biologicals, St. Petersburg, Russian Federation)

10.00-10.30

'NHP models for vaccines, adjuvants and delivery systems'

Edmond J. Remarque

(Biomedical Primate Research Centre, Rijswijk, The Netherlands)

10.30-11.00

Coffee Break

SESSION 6: ADJUVANTS I

Moderator: Edmond J. Remarque

(Biomedical Primate Research Centre, Rijswijk, The Netherlands)

11.00-11.30

'The functional effects of the Amplivant adjuvant (TLR1/2 ligand)'

Kees Melief

(ISA-Pharmaceuticals BV, Leiden, The Netherlands)

11.30-12.00

'Advanced kinetic analysis as a tool for formulation development and prediction of vaccine stability'

Sandrine Cigarini

(Sanofi Pasteur, Marcy l'Etoile, France)

12.00-12.30

'Evaluation of TLR-4-agonist and cAMP-based (dmLT) adjuvants in combination for delivery of anti-enterotoxigenic *E. coli* vaccine candidates by the intradermal or intramuscular routes'

Milton Maciel Jr.^{1,2}, Zoltan Beck^{2,3}, Stefanie Trop^{1,2}, Garry R. Matyas³, Steven Poole^{1,2}, Aaron Kim^{1,2}, Beth Ward^{1,2}, Zuzana Villar^{1,2}, Carl R. Alving³ and Michael G. Prouty¹

(¹ Naval Medical Research Center, Silver Spring, Maryland, USA; ² Henry M. Jackson Foundation, Bethesda, Maryland, USA; ³ Walter Reed Army Institute of Research, Silver Spring, Maryland, USA)

12.30-14.00

Lunch Break

SESSION 7: ADJUVANTS II

Moderator: Jean Haensler

(Sanofi Pasteur, Marcy l'Etoile, France)

14.00-14.30

'Adjuvanted *Staphylococcus aureus* vaccine an alternative for antibiotic treatment'

Bror Morein

(Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden)

14.30-15.00

'Adjuvant properties of the TLR7/8 agonist 3M-052'

Mark Tomai

(3M Company, St Paul, Minnesota, USA)

15.00-15.30

'Adjuvant safety: Role of T cell derived GPIb α protein in production of pro-inflammatory molecules PGE₂ and IL-1 β in primary human monocytes activated with muramyl dipeptide adjuvant'

Marina Zaitseva, Fengjie Liu, Tatiana Romantseva, Wells Wu, Rong-Fong Shen and Hana Golding

(Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA)

15.30-16.00

Tea Break

SESSION 8: GENERAL SESSION

Moderator: Mark Tomai

(3M Company, St. Paul, Minnesota, USA)

16.00-16.30

'Adjuvantome: Transcriptome data base for preclinical evaluation of vaccine adjuvant and immunotherapy'

Natsuko Kishishita and Ken J. Ishii

(Osaka University, Osaka, Japan)

16.30-17.00

'Clinical developments with Montanide ISA 51 VG adjuvant: A case study of a lung cancer vaccine (CIMAvax-EGF)'

Maria Lazaro

(SEPPIC, Paris, France)

17.00-17.30

'Characterization of protein vaccines containing an emulsion based adjuvant'

Michelle Archer

(IDRI, Seattle, Washington, USA)

SESSION 9: GENERAL SESSION

Moderator: Edmond Remarque

(Bimedical Primtae Research Centre, Rijswijk, The Netherlands)

09.00-09.30

'Restoring T-cell homeostasis in atherosclerosis using liposomal vaccine formulations'

Bram Slutter

(LACDR, University of Leiden, Leiden, The Netherlands)

09.30-10.00

'Clinical development of hydroxypropyl-beta-cyclodextrin (HP-bCD) as a vaccine adjuvant'

Takato Kusakabe and Ken J. Ishii

(University of Osaka, Osaka, Japan)

10.00-10.30

'Targeted delivery through formulation design: CAF24, a novel adjuvant for CTL induction'

Signe Tandrup Schmidt

(Statens Serum Institut, Copenhagen, Denmark)

10.30-11.00

Coffee Break

SESSION 10: GENERAL SESSION

Moderator: Erik Lindblad

(Brenntag Biosector, Frederikssund, Denmark)

11.00-11.30

'Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design of experiments approach'

Ryan Kramer

(IDRI, Seattle, Washington, USA)

11.30-12.00

'Development of a thermostable DNA vaccine formulation for challenging clinical environments'

Stephanie Ramos

(Inovio Inc., Blue Bell, Pennsylvania, USA)

12.00-12.30

'Identification of biomarkers that evaluate and screen new adjuvant candidates for safe and efficient influenza vaccines'

Takuo Mizukami

(National Institute of Infectious Diseases, Tokyo, Japan)

12.30

Lunch & Departure

* This provisional programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.

BRENNTAG

SEPPIC

inovio
PHARMACEUTICALS



NatureGeneTherapy.com
Gene-based vaccines & therapies

aldevron

DNAvaccine.com

CUREVAC
the RNA people®

BIOASTER
MICROBIOLOGY TECHNOLOGY INSTITUTE

IDRI

intravacc
innovating vaccines

hVIVO
better treatments, faster

SANOFI PASTEUR

VAXART